关于“中医”的报告
-
艾媒报告|2019-2021年中国中药材用户调研及延伸市场研究报告
本报告研究涉及企业/品牌/案例：同仁堂，片仔癀，东阿阿胶，太极集团，胡庆余堂，同仁牛黄清心丸，黄芪颗粒，雷氏丹参片，云峰气血口服液，太极五子衍宗丸，太极生力雄丸，仲景左归丸，一笑堂龟甲壳，白云山复方丹参片，天士力养血清脑颗粒，白云山夏桑菊颗粒，白云山板蓝根颗粒
随着居民消费水平的提升和健康保健意识的增强，总体健康需求在扩大，进而推动中医药市场的发展，2018年中国中药材市场规模达1246亿元，同比增长22.40%，预计到2024年，中药材市场规模将达2004亿元。
iiMedia Research（艾媒咨询）调查显示，2019年接近五成受访者购买过中药材，滋补养生和治病是购买中药材的两大目的。由于中医药应用范围广泛，中医药产业链不断扩展延伸，并加速扩展和整合。同仁堂、片仔癀、东阿阿胶等中药巨头企业纷纷布局中药材后市场，建设中药大健康产业，如植物提取物、保健食品、中药化妆品等，已成为我国生命健康产业中最具成长性的组成部分。
According to the iiMedia Research survey, nearly 50% of respondents have bought Chinese herbal medicines in 2019, and tonic sage and cure are the two main purposes for buying Chinese herbal medicines. Due to the wide range of applications of Chinese medicine, the Chinese medicine industry chain continues to expand and expand and accelerate the expansion and integration. Tongrentang, tablets, Dong'a gum and other Chinese medicine giant enterprises have laid out the chinese medicine after the market, the construction of chinese medicine large health industry, such as plant extracts, health food, Chinese medicine cosmetics, etc., has become China's life and health industry in the most growth component.
（以下为节选页，完整版共88页） -
艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告
本报告研究涉及企业/品牌/案例：白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业，培力控股,盛实百草,芍花堂,亳药千草,汇群中药
国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research（艾媒咨询）调查显示，有49%的受访用户倾向中医药治疗，与西药基本持平。2018年中国中药材市场规模达1246亿元，同比增长22.40%，在巨大的需求驱动下，中药材种植面积扩大，药材产量将会持续增长。
中药材主要包括上游种植、养殖市场，中游流通市场和下游销售市场三大环节。目前，中药饮片和中成药生产是中药产业的核心，主要包括中药加工，包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面，行业销售收入增速分别在2016和2018年触底回升，华润三九、中国中药、红日药业等上市公司表现良好；中药配方颗粒方面，2006-2016年，中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%，中药配方颗粒或将成为中药饮片加工行业应用广泛的产品；中成药方面，随着国家医改政策的推行，中成药消费需求趋于合理，中成药产量开始回落，但仍处于一个比较高的产量水平，云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。
Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well. -
